Biliary Tract Neoplasms Market

Market Overview:

The 7 major biliary tract neoplasms markets are expected to exhibit a CAGR of 7.21% during 2024-2034.

The biliary tract neoplasms market has been comprehensively analyzed in IMARC's new report titled "Biliary Tract Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Biliary tract neoplasms are malignant tumors that develop in the bile duct system, which includes the gallbladder, intrahepatic bile ducts, and extrahepatic bile ducts. These tumors are relatively rare but can be aggressive, significantly impacting the flow of bile, which aids in the digestion of fats. The symptoms of this ailment often mimic various other gastrointestinal disorders, making early diagnosis challenging. Common indications include jaundice, abdominal pain, unexplained weight loss, changes in stool and urine color, itching, etc. As the tumors progress, they can obstruct bile flow, leading to the aforementioned symptoms and potential complications. The diagnosis of biliary tract neoplasms involves a combination of imaging techniques, such as ultrasound, computed tomography scans, magnetic resonance imaging (MRI), and endoscopic retrograde cholangiopancreatography (ERCP). Tissue samples for a definitive diagnosis are obtained through procedures like fine-needle aspiration (FNA) or tissue biopsy. Additionally, blood tests measuring liver function and tumor markers are also recommended for patients.

The escalating prevalence of chronic inflammation of the bile ducts, that can cause cellular damage and promote the development of abnormal cells, is primarily driving the biliary tract neoplasms market. In addition to this, the inflating utilization of efficacious therapeutic interventions, including surgical resections, chemotherapy, and radiation, designed to effectively manage the ailment and impede its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies and palliative care options aimed at enhancing the quality of life for patients by mitigating symptoms and addressing discomfort is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures like laparoscopy and endoscopic interventions, which offer reduced postoperative complications and quicker recovery periods, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunotherapies and targeted therapies, since they harness the body's immune response to combat neoplastic growth in individuals suffering from the illness, is also augmenting the market growth. Furthermore, the ongoing research in the field of molecular biology, including the launch of gene therapy approaches that aim at introducing or modifying genetic material within cells to inhibit the growth of cancerous cells, is expected to drive the biliary tract neoplasms market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the biliary tract neoplasms market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for biliary tract neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the biliary tract neoplasms market in any manner.

Recent Developments:

• In April 2024, Jazz Pharmaceuticals announced that the company had completed the rolling submission of a Biologics License Application (BLA) to the US FDA seeking accelerated approval for the previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer.
• In November 2023, Merck stated that the United States FDA had authorized KEYTRUDA, Merck's anti-PD-1 medication, in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.

Key Highlights

• Biliary tract neoplasms account for less than 1% of all human cancers.
• The American Cancer Society reports that approximately 8,000 people are diagnosed with biliary tract malignancies each year.
• 40% of biliary tract cancers were due to intrahepatic cholangiocarcinoma.
• Metastatic biliary tract cancer has a five-year survival rate of less than five percent.
• Bile duct cancer is more common among the elderly. The typical age of patients in the United States diagnosed with bile duct cancer is in their seventies.

Drugs:

Durvalumab (Imfinzi), a therapeutic human monoclonal antibody that binds to and inhibits the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the United States, the European Union, Japan, and other countries in combination with gemcitabine and cisplatin for adults with advanced biliary tract cancer.

CAN04, an antibody, targets the interleukin-1 receptor accessory protein (IL1RAP) and inhibits IL-1α and IL-1β signaling. As a result, CAN04 can counteract the IL-1 system's contribution to the immune-suppressive tumor microenvironment and the development of chemotherapy resistance. CAN04 is being examined in two clinical trials.

AVA-6000 is under clinical development by Avacta Life Sciences for metastatic biliary tract cancer. The medication candidate is an affirmer coupled with pro-doxorubicin. It operates by targeting FAP. The medication candidate is being developed using Tufts technology and pre|CISION technology. It is delivered via the intravenous method.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the biliary tract neoplasms market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the biliary tract neoplasms market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current biliary tract neoplasms marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the biliary tract neoplasms market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the biliary tract neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the biliary tract neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of biliary tract neoplasms across the seven major markets?
• What is the number of prevalent cases (2018-2034) of biliary tract neoplasms by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of biliary tract neoplasms by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with biliary tract neoplasms across the seven major markets?
• What is the size of the biliary tract neoplasms patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of biliary tract neoplasms?
• What will be the growth rate of patients across the seven major markets?
   

Biliary Tract Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for biliary tract neoplasms drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the biliary tract neoplasms market?
• What are the key regulatory events related to the biliary tract neoplasms market?
• What is the structure of clinical trial landscape by status related to the biliary tract neoplasms market?
• What is the structure of clinical trial landscape by phase related to the biliary tract neoplasms market?
• What is the structure of clinical trial landscape by route of administration related to the biliary tract neoplasms market?